Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea

The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers t...

Full description

Saved in:
Bibliographic Details
Main Authors: Allard, Pierre Nicolas (Author) , Alhaj, Nareen (Author) , Lobitz, Stephan (Author) , Cario, Holger (Author) , Jarisch, Andreas (Author) , Grosse, Regine (Author) , Oevermann, Lena (Author) , Hakimeh, Dani (Author) , Tagliaferri, Laura (Author) , Kohne, Elisabeth (Author) , Kopp-Schneider, Annette (Author) , Kulozik, Andreas (Author) , Kunz, Joachim (Author)
Format: Article (Journal)
Language:English
Published: July, 2022
In: Haematologica
Year: 2022, Volume: 107, Issue: 7, Pages: 1577-1588
ISSN:1592-8721
DOI:10.3324/haematol.2021.278952
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2021.278952
Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/haematol.2021.278952
Get full text
Author Notes:Pierre Allard, Nareen Alhaj, Stephan Lobitz, Holger Cario, Andreas Jarisch, Regine Grosse, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Elisabeth Kohne, Annette Kopp-Schneider, Andreas E. Kulozik and Joachim B. Kunz for the German Sickle Cell Disease Study Group

MARC

LEADER 00000caa a2200000 c 4500
001 1837580766
003 DE-627
005 20230816184928.0
007 cr uuu---uuuuu
008 230227s2022 xx |||||o 00| ||eng c
024 7 |a 10.3324/haematol.2021.278952  |2 doi 
035 |a (DE-627)1837580766 
035 |a (DE-599)KXP1837580766 
035 |a (OCoLC)1389535414 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Allard, Pierre Nicolas  |d 1996-  |e VerfasserIn  |0 (DE-588)1280274166  |0 (DE-627)1833385039  |4 aut 
245 1 0 |a Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea  |c Pierre Allard, Nareen Alhaj, Stephan Lobitz, Holger Cario, Andreas Jarisch, Regine Grosse, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Elisabeth Kohne, Annette Kopp-Schneider, Andreas E. Kulozik and Joachim B. Kunz for the German Sickle Cell Disease Study Group 
264 1 |c July, 2022 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Vorabveröffentlichung Oktober 28, 2021 
500 |a Gesehen am 27.02.2023 
520 |a The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers the opportunity to answer this question, because >90% of patients are treated according to national guidelines recommending the use of hydroxyurea in all patients above 2 years of age. We analyzed the modifying effect of HbF-related genetic polymorphisms in 417 patients with homozygous SCD >2 years old who received hydroxyurea. HbF levels were correlated with higher total hemoglobin levels, lower rates of hemolysis, a lower frequency of painful crises and of red blood cell transfusions. The minor alleles of the polymorphisms in the γ-globin promoter (rs7482144), BCL11A (rs1427407) and HMIP (rs66650371) were strongly associated with increased HbF levels. However, these associations did not translate into lower frequencies of vaso-occlusive events which did not differ between patients either carrying or not carrying the HMIP and BCL11A polymorphisms. Patients on hydroxyurea carrying the γ-globin promoter polymorphism demonstrated substantially higher hemoglobin levels (P<10-4) but also higher frequencies of painful crises and hospitalizations (P<0.01) when compared to patients without this polymorphism. Taken together, these data indicate that the γ-globin, HMIP and BCL11A polymorphisms correlate with increased HbF in SCD patients on hydroxyurea. While HbF is negatively correlated with the frequency of painful crises and hospitalizations, this was not observed for the presence of known HbF-boosting alleles. 
700 1 |a Alhaj, Nareen  |e VerfasserIn  |4 aut 
700 1 |a Lobitz, Stephan  |e VerfasserIn  |4 aut 
700 1 |a Cario, Holger  |d 1966-  |e VerfasserIn  |0 (DE-588)113798717  |0 (DE-627)593161912  |0 (DE-576)172587654  |4 aut 
700 1 |a Jarisch, Andreas  |e VerfasserIn  |4 aut 
700 1 |a Grosse, Regine  |e VerfasserIn  |4 aut 
700 1 |a Oevermann, Lena  |e VerfasserIn  |4 aut 
700 1 |a Hakimeh, Dani  |e VerfasserIn  |4 aut 
700 1 |a Tagliaferri, Laura  |d 1986-  |e VerfasserIn  |0 (DE-588)1111667624  |0 (DE-627)865845808  |0 (DE-576)476237858  |4 aut 
700 1 |a Kohne, Elisabeth  |e VerfasserIn  |4 aut 
700 1 |a Kopp-Schneider, Annette  |e VerfasserIn  |0 (DE-588)1119160545  |0 (DE-627)872460444  |0 (DE-576)178153206  |4 aut 
700 1 |a Kulozik, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1025736567  |0 (DE-627)723892032  |0 (DE-576)167091638  |4 aut 
700 1 |a Kunz, Joachim  |d 1974-  |e VerfasserIn  |0 (DE-588)124297730  |0 (DE-627)085769029  |0 (DE-576)294107703  |4 aut 
773 0 8 |i Enthalten in  |t Haematologica  |d Pavia : Ferrata Storti Foundation, 2014  |g 107(2022), 7, Seite 1577-1588  |h Online-Ressource  |w (DE-627)814204899  |w (DE-600)2805244-4  |w (DE-576)424051125  |x 1592-8721  |7 nnas  |a Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea 
773 1 8 |g volume:107  |g year:2022  |g number:7  |g pages:1577-1588  |g extent:12  |a Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea 
856 4 0 |u https://doi.org/10.3324/haematol.2021.278952  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://haematologica.org/article/view/haematol.2021.278952  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230227 
993 |a Article 
994 |a 2022 
998 |g 124297730  |a Kunz, Joachim  |m 124297730:Kunz, Joachim  |d 910000  |d 910500  |d 50000  |e 910000PK124297730  |e 910500PK124297730  |e 50000PK124297730  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 13  |y j 
998 |g 1025736567  |a Kulozik, Andreas  |m 1025736567:Kulozik, Andreas  |d 910000  |d 910500  |e 910000PK1025736567  |e 910500PK1025736567  |k 0/910000/  |k 1/910000/910500/  |p 12 
998 |g 1119160545  |a Kopp-Schneider, Annette  |m 1119160545:Kopp-Schneider, Annette  |d 50000  |e 50000PK1119160545  |k 0/50000/  |p 11 
998 |g 1111667624  |a Tagliaferri, Laura  |m 1111667624:Tagliaferri, Laura  |d 910000  |d 910500  |e 910000PT1111667624  |e 910500PT1111667624  |k 0/910000/  |k 1/910000/910500/  |p 9 
998 |g 1280274166  |a Allard, Pierre Nicolas  |m 1280274166:Allard, Pierre Nicolas  |d 910000  |d 910500  |e 910000PA1280274166  |e 910500PA1280274166  |k 0/910000/  |k 1/910000/910500/  |p 1  |x j 
999 |a KXP-PPN1837580766  |e 427722248X 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"July, 2022","dateIssuedKey":"2022"}],"recId":"1837580766","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Vorabveröffentlichung Oktober 28, 2021","Gesehen am 27.02.2023"],"relHost":[{"titleAlt":[{"title":"journal of the European Hematology Association"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Pavia","dateIssuedDisp":"2014-","publisher":"Ferrata Storti Foundation","dateIssuedKey":"2014"}],"recId":"814204899","note":["Gesehen am 27.05.2022"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyureaHaematologica","id":{"eki":["814204899"],"issn":["1592-8721"],"zdb":["2805244-4"]},"pubHistory":["99.2014 -"],"language":["eng"],"part":{"text":"107(2022), 7, Seite 1577-1588","year":"2022","volume":"107","extent":"12","pages":"1577-1588","issue":"7"},"title":[{"subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation","title":"Haematologica","title_sort":"Haematologica"}]}],"id":{"eki":["1837580766"],"doi":["10.3324/haematol.2021.278952"]},"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Pierre Allard, Nareen Alhaj, Stephan Lobitz, Holger Cario, Andreas Jarisch, Regine Grosse, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Elisabeth Kohne, Annette Kopp-Schneider, Andreas E. Kulozik and Joachim B. Kunz for the German Sickle Cell Disease Study Group"]},"person":[{"family":"Allard","given":"Pierre Nicolas","role":"aut","display":"Allard, Pierre Nicolas"},{"display":"Alhaj, Nareen","role":"aut","given":"Nareen","family":"Alhaj"},{"family":"Lobitz","display":"Lobitz, Stephan","role":"aut","given":"Stephan"},{"display":"Cario, Holger","given":"Holger","role":"aut","family":"Cario"},{"family":"Jarisch","display":"Jarisch, Andreas","given":"Andreas","role":"aut"},{"display":"Grosse, Regine","given":"Regine","role":"aut","family":"Grosse"},{"role":"aut","given":"Lena","display":"Oevermann, Lena","family":"Oevermann"},{"role":"aut","given":"Dani","display":"Hakimeh, Dani","family":"Hakimeh"},{"given":"Laura","role":"aut","display":"Tagliaferri, Laura","family":"Tagliaferri"},{"family":"Kohne","role":"aut","given":"Elisabeth","display":"Kohne, Elisabeth"},{"role":"aut","given":"Annette","display":"Kopp-Schneider, Annette","family":"Kopp-Schneider"},{"family":"Kulozik","display":"Kulozik, Andreas","given":"Andreas","role":"aut"},{"family":"Kunz","display":"Kunz, Joachim","role":"aut","given":"Joachim"}],"language":["eng"],"title":[{"title":"Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea","title_sort":"Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea"}]} 
SRT |a ALLARDPIERGENETICMOD2022